There is a middle ground for those who perceive management as not performing and want to replace some of the executive team. The compromise would be salary clawbacks and move that compensation to more deliverable base in increased ability for more options instead. NP does make a salary much higher than many in small Biotech. The Vir CEO has a salary in the $900k area and has increased shareholder value along with delivering. So instead of causing a major distraction at a critical juncture in Virologix's history, that option would perhaps satisfy those in the different camps. Just throwing it out there...